Exagen Hits Record Revenue, Signals Stronger Financial Discipline in Autoimmune Market

CARLSBAD, CA – May 11, 2026 – Exagen Inc. (Nasdaq: XGN) today reported a robust start to 2026, posting record first-quarter revenue and demonstrating significant progress in operational efficiency. The autoimmune diagnostics company announced total revenues of $17.3 million, a 12% increase from the same period last year, driven by the growing adoption of its flagship AVISE testing portfolio. While navigating the path to profitability, the company's improved cost management and strategic financial maneuvers are drawing positive attention from market analysts.

Growth Fueled by Efficiency Gains

Exagen's first-quarter performance paints a picture of a company executing on a dual strategy of top-line growth and bottom-line discipline. The record $17.3 million in revenue was underpinned by a 10% increase in the volume of its AVISE CTD tests, a key diagnostic tool for complex autoimmune diseases. This growth signals strengthening demand and deeper penetration within its target market of rheumatology specialists.

Financially, the company showcased notable improvements in operational efficiency. The adjusted EBITDA loss, a non-GAAP metric that excludes certain non-cash and non-recurring expenses, narrowed by 14% to $2.2 million, compared to a $2.5 million loss in the first quarter of 2025. This improvement suggests that the company’s efforts in "disciplined execution and effective revenue cycle management," as noted by President and CEO John Aballi in the company's official release, are bearing fruit. The company's gross margin also held steady at 59.0%, a slight improvement over the prior year.

However, the journey towards profitability remains a work in progress. The company reported a net loss of $3.97 million for the quarter, slightly wider than the $3.75 million loss in Q1 2025. This was attributed in part to higher operating expenses, including research and development, which rose as the company invests in future innovation. Despite the wider net loss, the net loss per share improved to $(0.17) from $(0.20), a change reflecting a higher number of weighted-average shares outstanding.

The AVISE CTD Engine Powers Commercial Success

At the heart of Exagen's commercial momentum is its AVISE CTD test. The company achieved a record trailing-twelve-month average selling price (ASP) for the test, which climbed to $444, a 6% increase from the previous year. This rising ASP, coupled with growing test volumes, is a powerful combination that directly fuels revenue growth and indicates strong market acceptance and successful reimbursement strategies.

The AVISE CTD test is a sophisticated blood test designed to help clinicians diagnose challenging autoimmune conditions like lupus with greater clarity. Its clinical value is enhanced by proprietary technologies like the Cell-Bound Complement Activation Products (CB-CAPs), which provide unique insights into the underlying disease process. By focusing its commercial efforts on the approximately 5,000 rheumatologists in the United States, Exagen has cultivated a loyal user base that values the diagnostic clarity its products provide. The continued growth in both volume and price suggests that clinicians and payors alike see tangible value in the test's ability to enable earlier and more accurate diagnoses, potentially leading to better patient outcomes and lower long-term healthcare costs.

Strategic Positioning in a Growing Market

Exagen operates within the dynamic and rapidly expanding autoimmune diagnostics market, which is projected to grow from over $6 billion in 2025 to more than $11 billion by the early 2030s. This growth is fueled by an increasing prevalence of autoimmune disorders and significant technological advancements. While the market is dominated by large diagnostic corporations like Roche, Abbott, and Siemens Healthineers, Exagen has carved out a successful niche as a specialized provider for rheumatology.

Instead of competing as a generalist laboratory, the company has positioned itself as an expert partner to rheumatologists, offering a specialized testing portfolio and deep clinical expertise. This focused strategy allows it to compete effectively on clinical value rather than sheer volume. However, the path is not without challenges. The diagnostics industry is characterized by complex reimbursement landscapes and rigorous regulatory requirements. Exagen's ability to consistently increase the ASP for its flagship test demonstrates a successful navigation of these hurdles, which remains a critical factor for its long-term financial health.

A Deliberate Approach to Financial Management

Beyond its product strategy, Exagen's first-quarter results also shed light on its deliberate financial management. The company ended the quarter with approximately $21.5 million in cash and cash equivalents, a figure it noted was "ahead of expectations." This was attributed to a "long-standing strategy to hold claims in the first quarter."

This practice of intentionally delaying the submission of some reimbursement claims is a form of working capital management. While it results in temporarily elevated accounts receivable on the balance sheet, it allows the company to control the timing of its cash inflows. By managing its billing cycle this way, Exagen can potentially smooth out cash flow over the fiscal year and maintain a stronger cash position at key reporting periods. This strategic approach to its revenue cycle underscores a level of financial sophistication aimed at maximizing stability as the company invests in growth and moves toward profitability.

Wall Street Sees Upside as Company Reaffirms Guidance

Exagen's performance and strategic positioning have earned a bullish reception from Wall Street. The company reaffirmed its full-year 2026 revenue guidance of $70 million to $73 million, signaling confidence in its ability to maintain its growth trajectory. Analyst consensus is strong, with most ratings falling into the "Strong Buy" or "Moderate Buy" categories.

Average price targets from analysts suggest a potential upside of over 200% from the stock's current levels, reflecting a belief in the company's long-term value proposition. Market watchers expect Exagen to continue its volume and revenue growth while steadily narrowing its losses, with management having previously indicated a goal of achieving positive Adjusted EBITDA within the next 12 to 18 months and positive free cash flow in 2027. While risks related to debt, commercial execution, and payor concentration remain, the strong start to 2026 has reinforced the narrative of a company on a clear path to becoming a profitable leader in the autoimmune diagnostics space.